$149M Goodwill Impairment Drives Azenta's Widening Q2 GAAP Loss; Long-Range Plan Extended
AZTA sits 16% above its 52-week low of $19.87 on elevated volume (1.9× avg).
Summary
Azenta reported Q2 FY2026 results, revealing a significant GAAP operating loss of $165.8 million, primarily driven by a $149.1 million non-cash goodwill impairment charge. This led to a diluted loss per share from continuing operations of $(3.41). While revenue from continuing operations was $145 million (up 1% year-over-year), organic revenue declined approximately 3%. Management also extended its long-range plan timeline from 2028 to 2029 and updated its FY2026 guidance, signaling a more challenging outlook. This substantial impairment and widening loss are highly material for the company, indicating significant asset value write-downs and operational difficulties, which could negatively impact investor confidence. Investors will monitor the ongoing Multiomics transformation and the company's ability to execute its revised strategic timeline.
At the time of this announcement, AZTA was trading at $23.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $19.87 to $41.73. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.